WO2007010976A1 - Composition inhibant la prise de poids a base de d-psicose et utilisation associee - Google Patents

Composition inhibant la prise de poids a base de d-psicose et utilisation associee Download PDF

Info

Publication number
WO2007010976A1
WO2007010976A1 PCT/JP2006/314366 JP2006314366W WO2007010976A1 WO 2007010976 A1 WO2007010976 A1 WO 2007010976A1 JP 2006314366 W JP2006314366 W JP 2006314366W WO 2007010976 A1 WO2007010976 A1 WO 2007010976A1
Authority
WO
WIPO (PCT)
Prior art keywords
psicose
obesity
composition
overweight
body weight
Prior art date
Application number
PCT/JP2006/314366
Other languages
English (en)
Japanese (ja)
Inventor
Mitsuhiro Nagata
Original Assignee
Teikoku Seiyaku Co., Ltd.
National University Corporation Kagawa University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Seiyaku Co., Ltd., National University Corporation Kagawa University filed Critical Teikoku Seiyaku Co., Ltd.
Publication of WO2007010976A1 publication Critical patent/WO2007010976A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates to the use of D-psicose to suppress weight gain and / or to reduce overweight. More specifically, the present invention can suppress excessive weight gain due to various causes, reduce overweight, prevent and reduce obesity, and prevent excessive weight gain or overweight.
  • the present invention relates to a composition, food, food material, food additive, beverage, drinking water, drug, drug substance, and feed containing D-psicose and / or a derivative thereof suitable for a person and / or animal.
  • the present invention also relates to a method for suppressing weight gain and / or reducing overweight due to various causes.
  • rare sugars exist in nature, the abundance is extremely small. Rare sugars are divided into aldoses, ketoses and alcohols by chemical structure. Examples of aldoses include D-alose strength. Examples of ketoses include D-psicose strength. Examples of alcohols include aritol. However, since most of these rare sugars have been difficult to obtain because they were not mass-produced in the past, little research has been conducted on their physiological and pharmacological activities. Recently, a large-scale production method using enzymes was developed by Prof. Irimori et al., Faculty of Agriculture, Kagawa University, and some rare sugars such as D-psicose, D-allose, and aritol were produced. Research is progressing.
  • Non-patent Document 1 suppression of D-Glucose transport in the isolated intestinal tract (Non-patent Document 1), promotion of insulin secretion from rat spleen j8 cell line (Patent Document 1), vascular endothelial cells Suppression of MCP-1 secretion from strains (Patent Document 1), etc., and in vivo experiments, body fat accumulation mitigating action (Non-Patent Document 2), and not becoming energy in vivo (Non-Patent Document 3), etc.
  • Non-Patent Document 1 suppression of D-Glucose transport in the isolated intestinal tract
  • Patent Document 1 promotion of insulin secretion from rat spleen j8 cell line
  • Patent Document 2 vascular endothelial cells Suppression of MCP-1 secretion from strains
  • Non-Patent Document 2 body fat accumulation mitigating action
  • Non-patent Document 1 suppression of D-glucose transport in the isolated intestinal tract (Non-patent Document 1), promotion of insulin secretion from the rat spleen j8 cell line (Patent Document 1), vascular endothelial cells Suppression of MCP-1 secretion from strains (Patent Document 1), action to suppress the accumulation of neutral fat in adipocytes (Non-Patent Documents 2 and 3), etc. Reference 4), and the energy in the living body, which is not unique (Non-Patent Document 5), have been clarified.
  • Non-Patent Document 1 Fiscal 1999 Science and Technology Comprehensive Research Commission Regional Lead Research Research Result Report “Study on Mechanisms of Action of Rare Sugars as Pharmaceuticals” Kagawa Medical University, Masaaki Tokuda, Yoshishi Konishi, Maeda Tsuji, 2000
  • Non-Patent Document 2 2005 Japanese Biochemical Society Abstract (Kobe) “Effect of monosaccharides on fat cells” Kagawa University School of Medicine, Madoka Saito and 4 others.
  • Non-Patent Document 3 2006 International Biochemical Society Abstract (Kyoto) “Effects of Rare Sugars on the Properties of 3T3—LI Adipocytes.”
  • Non-patent document 4 Fiscal 1999 Science and Technology Comprehensive Research Commission Regional Leading Research Research Results Report “Nutritional Evaluation of Rare Sugars Using Rats and Their Application to Food” Kagawa University Faculty of Agriculture, Hiroo Suzuki, Matsuo Tatsuhiro, Hashiguchi Mineo, 2000
  • Non-Patent Document 5 Fiscal 2000 Science and Technology Research Fund Regional Lead Research Research Results Report “Nutritional Evaluation of Rare Sugars Using Rats and Application to Food” Kagawa University Faculty of Agriculture, Hiroo Suzuki, Matsuo Tatsuhiro, Hashiguchi Mineo, 2001
  • Patent Document 1 International Publication Number W003 / 097820
  • D-psicose is a sugar with a refreshing sweetness that is about 60% stronger than sucrose, and abnormal sugar metabolism is closely related to abnormal fat metabolism, so this rare sugar has an anti-obesity effect The potential is great. Therefore, we investigated the anti-obesity effect of D-psicose using human obesity model animals.
  • the purpose of the present invention based on the results of the above studies is to achieve D-psicose and / or suitable for humans and animals that are capable of suppressing overweight and reducing overweight, and that require prevention of obesity and improvement of obesity.
  • the present invention provides a composition, a food, a food material, a food additive, a beverage, drinking water, a drug, a pharmaceutical raw material, a feed and the like containing the derivative.
  • Another object of the present invention is to provide a method for suppressing an excessive increase in body weight due to various causes and reducing an overweight.
  • the present invention includes D-psicose, and suppresses excessive weight gain and / or A gist is a composition characterized by reducing overweight.
  • D-psicose power is formulated to include ⁇ 90% by weight
  • the present invention includes D-psicose and is formulated to include D-psicoseca ⁇ -90% by weight.
  • the gist of the present invention is a composition characterized in that it suppresses and / or reduces overweight.
  • D-psicose is D-psicose and Z or a derivative thereof
  • the present invention contains D-psicose and Z or a derivative thereof, preferably formulated so that D-psicose and Z or a derivative thereof is contained in an amount of 90 to 90% by weight.
  • the gist of the present invention is a composition characterized in that it suppresses overweight and / or reduces overweight.
  • the present invention is characterized in that any of the above-described yarns and adults is used for a person and Z or an animal who need to suppress overweight and / or reduce overweight.
  • the gist is a method of suppressing overweight and / or reducing overweight.
  • the gist of the present invention is a composition comprising D-psicose and characterized by preventing obesity and improving Z or obesity status.
  • D-psicose strength is formulated to include 90% by weight
  • the present invention includes D-psicose, which is formulated to include D-psicose ca ⁇ -90% by weight, to prevent obesity.
  • a thread and composition characterized by improving Z and obesity status.
  • D-psicose is D-psicose and Z or a derivative thereof
  • the present invention contains D-psicose and Z or a derivative thereof, preferably formulated so that D-psicose and Z or a derivative thereof is contained in an amount of 90 to 90% by weight.
  • the gist of the present invention is a composition characterized by preventing obesity and improving Z or obesity status.
  • the present invention also provides a method for preventing and preventing obesity, characterized by using any of the compositions described above for people and Z or animals that require prevention of obesity and improvement of Z or obesity status.
  • the gist is a method for improving an obesity state.
  • the present invention comprises D-psicose and / or a derivative thereof as an active ingredient, and an excess of body weight.
  • a composition having an inhibitory effect on increase and / or an effect of reducing overweight and / or a composition having an effect of preventing obesity due to various causes and / or an effect of improving obesity, and these compositions are used. It is possible to provide a method for suppressing overweight and / or reducing overweight and / or a method for preventing and / or improving obesity by various causes.
  • the present invention is characterized in that it suppresses excess body weight gain and / or reduces overweight, and comprises D-psicose and / or a derivative thereof as an active ingredient, for foods, health foods, and patients.
  • the present invention uses a composition containing D-psicose and / or a derivative thereof to suppress overweight and / or reduce overweight and / or prevent obesity caused by various causes.
  • a method for improving obesity can be provided.
  • FIG.l Effect of repeated administration of D-Psicose on body weight of Zucker (fa / fa) rats [In the figure, *; p ⁇ 0.05, * *; p ⁇ 0.001 (vs distilled water administration group) ⁇ .
  • FIG. 2 shows the effect of D-Psicose on the body weight of mice administered with Aurothioglucose (ATG) [in the figure, * *; p ⁇ 0.01 (vs ATG control group)].
  • Aurothioglucose Aurothioglucose
  • D-psicose With regard to D-psicose, in recent years, with the advent of epimerase (see, for example, JP-A-6-125776), for example, it has become possible to produce it from D-fructose, which is a monosaccharide abundant in nature. Although it is still expensive, it has become relatively easy to obtain. It was found that by using D-fructose as a raw material, the problem of raw material cost was solved and a hetero-oligosaccharide expected to have a new physiological activity based on D-psicose was obtained. Among monosaccharides, D-psicose is a hexasaccharide having a ketone group as a reducing group.
  • D-psicose is known to have D and L isomers as optical isomers.
  • D-psicose is a known substance but rarely exists in nature, so it is defined as “rare sugar” according to the definition of the International Association of Rare Sugars.
  • Rare sugars can be defined as monosaccharides (aldoses, ketoses and sugar alcohols) that rarely exist in nature. Also in the present invention, it is a rare sugar based on the above definition, and preferably ketose D-psicose. This definition is ambiguous because it is not a definition of sugar structure or properties. That is, there is no definition of an amount such as a rare sugar that is less than a certain amount. However, there are six types of aldoses that are generally abundant in nature: D-glucose, D-galactose, D-mannose, D-ribose, D-xylose, and L-arabinose. Other aldoses are defined as rare sugars. Is done.
  • ketose D-fructose exists, and other ketoses are rare sugars.
  • Other ketoses include D-tagatose, D-sorbose, L-fructose, L-psicose, L-tagatose, and L-sorbose.
  • Sugar alcohol can be produced by reducing monosaccharides, but D-sorbitol is relatively large in nature, but the others are quantitatively small, so these are also rare sugars.
  • the rare sugar D-psicose used in the present invention has been developed as a method for mass production of rare sugars from monosaccharides existing in large quantities in nature. Can be manufactured.
  • D-psicose derivative used in the present invention will be described.
  • a compound obtained by converting the structure of a molecule from a certain starting compound by a chemical reaction is called a derivative of the starting compound.
  • Derivatives of hexose containing D-psicose include sugar alcohols (when monosaccharides are reduced, aldehyde groups and ketone groups become alcohol groups and polyhydric alcohols of the same number as carbon atoms), uronic acid ( It is an oxidized monosaccharide alcohol group.
  • D-glucuronic acid, galacturonic acid, and mannuronic acid are known.
  • Amino sugar substituted with OH group NH2 group of sugar molecule, darcosamine, chondrosamine) , Glycosides, etc. are common, but are not limited thereto.
  • D-psicose is considered to be less toxic to animals, with no reported toxicity to humans.
  • D-psicose is a sugar with a refreshing sweetness that dissolves in water and is about 60% stronger than sucrose. The sweetness is refined and refreshing, and it resembles the sweetness of fratatose rather than the discomfort associated with bitterness and astringency like saccharin.
  • D-psicose is in harmony with other tastes of various substances such as acidity, salt to taste, astringency, umami, bitterness, etc., for sweetening and taste improvement of ordinary foods and beverages, quality improvement, etc. Can be advantageously used.
  • Compositions targeted by the present invention are edible containing D-psicose and / or its derivatives And / or is any medicinal composition.
  • a composition containing D-psicose as an active ingredient also serves as a food additive, food material, food and drink, pharmaceutical / quasi-drug, and feed power to suppress overweight and / or reduce overweight.
  • the group power is also selected. Utilizing the functionality of the composition, it became possible to develop healthy foods and drinks, foods with nutritional foods and drinks for patients, and feed for domestic animals such as livestock, poultry and fish.
  • the food or drink is a functional food, a nutritional supplement, or a healthy food or drink for suppressing excessive increase in body weight and / or reducing overweight.
  • the above feed is a feed for livestock, poultry and pets for suppressing excess weight gain and / or reducing overweight.
  • the food material of the composition containing the above-mentioned D-psicose as an active ingredient can be used in any form of food, beverage or feed.
  • composition containing D-psicose of the present invention as an active ingredient, its content is not particularly limited, but it depends on the degree of intended function, usage mode, usage amount, etc. It can be adjusted as appropriate, for example 0.05 to 100% by mass.
  • the composition for suppressing overweight and / or reducing overweight can be used for the human body, other foods and drinks, pharmaceuticals, feeds, and external preparations for skin. In addition, it can be taken by mouth or applied to the skin.
  • foods and drinks when blended in foods and drinks, foods and drinks can be provided for treating or preventing diseases that should suppress excess body weight gain and / or reduce overweight. From the prevention effect, it can be expected to be used as health food, nutritional food, etc. In addition, it can be used for livestock and feed or feed for Z or fish. By using it in the human body, other foods and drinks, pharmaceuticals, fertilizers, feeds, and external preparations for skin, it is possible to obtain an effect of treating or preventing an overweight and / or a disease that should reduce overweight. .
  • D-psicose and / or a derivative thereof is usually blended so as to be contained in an amount of 0.1 to 50% by weight in the composition. Preferably it is 1-50 weight%, More preferably, it is 10-30 weight%. However, if the content is low, it is sufficient to increase the intake of the composition. If the content is high, if the content is low, the intake of the composition may be reduced. Therefore, with regard to the blending ratio, it can be used at a blending ratio close to the lower limit for ordinary foods and beverages. When used in pharmaceuticals, tablets and capsules, it can be used at a blending ratio close to the upper limit.
  • the dosage should be determined by the individual's age, weight and symptoms, etc., but in many cases the effective dose is D-psicose per adult It is appropriate to take 1-50g in divided doses before meals, after meals or with meals.
  • the dose of D-psicose and Z or its derivatives is preferably taken as an oral dose of 0.3 to 50 g daily for adults as D-psicose, but may be increased or decreased appropriately depending on age and symptoms. Is possible.
  • the daily anti-obesity and Z or ameliorating agent of the present invention should be taken once a day, or divided into 2 or 3 times a day at an appropriate interval, or before, after or after meals. Is preferred.
  • the composition of the present invention When used for foods, it is in a form as it is, a form diluted with oil, a milk form meal, or a form to which a carrier generally used in the food industry is added. It may be prepared.
  • the beverage form is a non-alcoholic beverage or an alcoholic beverage.
  • Non-alcoholic beverages include, for example, non-carbonated beverages such as carbonated beverages, fruit juice beverages, and nectar beverages, soft drinks, sports beverages, tea, coffee, cocoa, etc.
  • the form of food can be mentioned.
  • Main departure Examples of the use of the light composition as a food material or food additive for the purpose of improving the above abnormalities of carbohydrate metabolism and / or lipid metabolism include powders or granules dissolved in tablets, capsules, beverages, etc. Solids, semi-solids such as jelly, liquids such as drinking water, and high-concentration solutions used after dilution.
  • the composition of the present invention can be appropriately added to foods to provide health foods or sick foods for the purpose of obesity prevention and Z
  • vitamins, carbohydrates, pigments, fragrances and the like that are usually added to foods can be appropriately blended.
  • the food can be eaten in any form, liquid or solid. It can be eaten as a soft capsule encapsulated by gelatin or the like.
  • Capsules are made, for example, with a gelatin film prepared by adding water to raw gelatin and dissolving it, and then adding a plasticizer (such as glycerin or D-sorbitol).
  • the food material and food additive of the present invention will be described. Since D-psicose is soluble in water, it can be easily added to beverages such as coffee and juice, confectionery, and various processed foods. Furthermore, the composition of the present invention can be appropriately added to foods and / or food materials to obtain processed foods for health and / or patients for the purpose of preventing obesity and / or improving obesity. .
  • the composition of the present invention is used as a food material and / or a food additive for preparing food that can be eaten, taken or taken by a person and animals who need obesity prevention and / or improvement of obesity with a general meal. It can be used to prevent excessive weight gain, improve overweight, increase QOL, reinforce the effects of drugs or other foods used for similar purposes, and reduce the amount used. Can be reduced.
  • the dosage should be determined by the individual's age, weight and symptoms, etc. In many cases, effective doses are rare sugars per day. It is appropriate to take -50g in divided doses before meals, after meals or with meals.
  • the use form of the composition of the present invention as a food material or food additive for the purpose of preventing obesity and / or ameliorating obesity, etc. includes powders dissolved in tablets, capsules, beverages, etc. Solid agents such as granules, semi-solid bodies such as jelly, drinking water, etc. Liquid, high-concentration solution to be used after dilution. Furthermore, the composition of the present invention can be appropriately added to foods to provide health foods or sick foods for the purpose of preventing obesity and / or improving obesity.
  • the drinking water of the present invention is a colorless and transparent, odorless, almost tasteless aqueous solution containing 1 to 5% by weight of D-psicose and / or a derivative thereof.
  • the amount is preferably 1.5 to 4% by weight, more preferably 2 to 3% by weight. If it is less than 1% by weight, the effect of preventing obesity and / or improving the condition of obesity is not sufficient. If it exceeds 5% by weight, the sweetness derived from D-psicose, which has 60% sweetness of sugar, can be felt.
  • This drinking water is colorless and transparent, and has a strong sweetness that smells. Therefore, it can be used as drinking water as it is, and can also be used for cooking rice, cooking, tea and coffee.
  • the agent of the present invention will be described.
  • the present inventor examined in detail the effect of D-psicose on the body weight of rats using genetic and experimental obesity model animals. As a result, we found that D-psicose has the effect of suppressing weight gain and reducing overweight.
  • Drugs containing D-psicose and / or its derivatives as an active ingredient for the purpose of preventing obesity and / or improving obesity status are used alone or in general.
  • Formulated with appropriate additives such as form, stabilizer, preservative, binder, disintegrant, liquid, granule, fine granule, powder, tablet, capsule, pill, ointment, patch, spray
  • An appropriate dosage form such as an agent, spray or injection can be selected and formulated and administered orally, nasally, transdermally or intravenously.
  • composition of the present invention When the composition of the present invention is applied clinically as a drug, D-psicose and / or a derivative thereof as an active ingredient is used as a solid, semi-solid or liquid pharmaceutical carrier such as a diluent, an excipient. It is desirable to prepare a preparation containing additives such as an agent and a stabilizer.
  • the ratio of the active ingredient to the carrier component can vary between 1 and 90% by weight.
  • the dosage form and mode of administration are liquids, granules, fine granules, powders, tablets, capsules, pills, ointments, patches, sprays, sprays or injections. Or it may be administered orally with the bulk. When used as a liquid, it may be administered nasally or intravenously in addition to oral administration.
  • a pharmaceutical organic or organic solid, semi-solid or liquid carrier, solubilizer or diluent suitable for oral administration, nasal administration, transdermal administration or intravenous administration is used as a composition of the present invention. It can be used to prepare as a medicine. Water, gelatin, lactose, starch, magnesium stearate, talc, animal and vegetable oil benzyl alcohol, gum, polyalkylene glycol, petroleum oil, coconut oil, lanolin, or other carriers used in medicine All can be used as a carrier for a drug containing the composition of the present invention. In addition, stabilizers, moistening agents, emulsifiers, and salts for adjusting the osmotic pressure and maintaining the pH of the compounding agent can be appropriately used as auxiliary agents.
  • the drug containing the composition of the present invention contains other pharmaceutically effective ingredients that can be appropriately administered together with the drug of the present invention in obesity prevention and / or improvement of obesity status. May be.
  • the drug containing the composition of the present invention contains other pharmaceutically effective ingredients that can be appropriately administered together with the drug of the present invention in obesity prevention and / or improvement of obesity status. May be.
  • the corresponding amount (ratio) is preferably 1 to 80% by weight.
  • the clinical dose is preferably taken as an oral dose of 1 to 50 g daily for adults as D-psicose and / or its derivatives, but may be increased as appropriate depending on age, symptoms, etc. It can also be reduced.
  • the daily dose of the agent of the present invention is preferably administered once a day or divided into two or more times at an appropriate interval, or before, after or with a meal.
  • D-psicose and / or its derivative is used as a drug substance as a general excipient, stabilizer, preservative, It can also be used for purposes such as binders and disintegrants. Alternatively, for example, when obesity appears secondary, it is necessary to improve the obesity state in addition to the treatment of the causative disease.
  • the product can also be used as a raw material for preparation as described above. In this case, the amount of D-psicose and / or its derivative used and the ratio with other drugs can be appropriately adjusted depending on the content or nature of these therapeutic agents in the preparation.
  • Type of bait used in the experiment mouse “rat” hamster CE2 manufactured by Claire Japan
  • Feeding method free intake
  • fa / fa rats Ten-week-old male Zucker (fa / fa) rats (hereinafter referred to as Zuc (fa)) were used. These animals were administered in distilled water (control group), D-psicose 0.5 g / kg (P0.5), D-psicose lg / kg (Pl), D-psicose 2 g / kg. Group (P2), D-psicose 4g / kg group (P4), 5 groups Divided into. D-psicose was dissolved in distilled water and the administration volume was 10 mL / kg.
  • the above D-psicose solution or distilled water was orally administered by gavage once a day.
  • Body weight was measured at 3 or 4 day intervals. The measured values were expressed as mean values and standard errors, and were performed using a significant difference test or a Tukey multiple range test.
  • mice 500 mg / kg was administered intraperitoneally.
  • 7 mice died out of 60 mice administered ATG, and 53 mice survived.
  • animals with a body weight greater than the mean value of the animals (non-ATG control group) that had not been administered ATG (non-ATG control group) + standard deviation X2 were regarded as experimentally fertile mice.
  • the 53 surviving mice 26 were experimental obese mice.
  • mice are divided into 3 groups: distilled water administration group (ATG control group), D-psicose 1% aqueous solution administration group (ATG + P1%) and D-psicose 10% aqueous solution administration group (ATG + P10%). It was. These D-psicose aqueous solution administration groups were given D-psicose aqueous solution from the 15th day to the 28th day of ATG administration and distilled water after the body weight measurement on the 18th day as drinking water.
  • Body weight was measured at 3 or 4 day intervals. The measured values are expressed as average values and standard errors. 3 ⁇ 4, g, Test iiTukey multiple range test is used.
  • the weight gain of animals in the D-psicose administration group was less than that in the control group.
  • the body weight in the P4 group was significantly different from the control group at all measurement points after the 10th day of D-psicose administration.
  • the P2 group showed significantly less body weight than the control group on day 21 after D-psicose administration (Fig. 1).
  • the body weight of the animals in the ATG + P10% group decreased immediately after administration of D-psicose, and during the period of administration of D-psicose (from day 15 to day 28 of ATG administration), the body weight of the animals in the non-ATG control group There was no significant difference. Even after changing the drinking water from D-psicose 10% aqueous solution to distilled water on the 28th day of ATG administration, the body weight of the animals in the ATG + P10% group remained decreased, and the body weight of the animals in the non-ATG control group There was no significant difference between the two (Figure 2).
  • the body weight decreased to about the same weight as normal mice immediately after using 10% D-psicose aqueous solution as drinking water.
  • the weight loss when D-psicose 10% aqueous solution was used as drinking water remained even after the drinking water was changed to distilled water.
  • the body weight was reduced by the D-psicose 10% aqueous solution. The body weight was not significantly lower than that of normal mice.
  • D-psicose and / or a derivative thereof has the effect of suppressing weight gain and reducing the weight gain in obese animals. I got it. This is a result of presuming that D-psicose and / or its derivatives show an effect of preventing obesity and / or improving obesity in humans, and provides a new means for preventing and dealing with obesity. is there.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention est destinée à inhiber la prise excessive de poids induite par diverses causes et à réduire la surcharge pondérale. A cet effet, l'invention propose une composition comprenant du D-psicose servant à inhiber la prise excessive de poids et/ou à réduire la surcharge pondérale ; et une composition comprenant du D-psicose destinée à assurer une prévention contre l'obésité et/ou à réduire l'obésité. Dans ces compositions, le D-psicose est ajouté à une quantité comprise entre 1 et 90 % en poids en fonction du poids total de la composition, et représente un composé chimique D-psicose et/ou un dérivé de celui-ci. L'invention concerne également une méthode permettant d'inhiber la prise excessive de poids et/ou de réduire la surcharge pondérale chez un individu et/ou un animal nécessitant un tel traitement, qui consiste à administrer la composition à l'individu ou à l'animal. L'invention concerne également une méthode de prévention contre l'obésité et/ou de réduction de l'obésité chez un individu ou un animal nécessitant un tel traitement, qui consiste à administrer la composition à l'individu ou à l'animal.
PCT/JP2006/314366 2005-07-20 2006-07-20 Composition inhibant la prise de poids a base de d-psicose et utilisation associee WO2007010976A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2005209654 2005-07-20
JP2005-209654 2005-07-20
JP2006196753A JP5645183B2 (ja) 2005-07-20 2006-07-19 Ｄ−プシコースを有効成分として含む肥満状態改善剤
JP2006-196753 2006-07-19

Publications (1)

Publication Number Publication Date
WO2007010976A1 true WO2007010976A1 (fr) 2007-01-25

Family

ID=37668848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/314366 WO2007010976A1 (fr) 2005-07-20 2006-07-20 Composition inhibant la prise de poids a base de d-psicose et utilisation associee

Country Status (2)

Country Link
JP (1) JP5645183B2 (fr)
WO (1) WO2007010976A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008059625A1 (fr) * 2006-11-17 2008-05-22 National University Corporation Kagawa University Utilisation de la fonction de sucre rare en tant que promoteur de la migration de glucokinase depuis le noyau jusqu'au cytoplasme
US9259022B2 (en) 2013-03-15 2016-02-16 Tate & Lyle Ingredients Americas Llc Sweetener
US9491960B2 (en) 2013-03-15 2016-11-15 Tate & Lyle Ingredients Americas Llc Sweetener
US9854827B2 (en) 2013-03-15 2018-01-02 Tate & Lyle Ingredients Americas Llc Sweetener

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007100102A1 (fr) * 2006-03-03 2007-09-07 National University Corporation Kagawa University Composition nematicide et procede d'eradication de nematodes l'utilisant
JP5639759B2 (ja) * 2007-05-18 2014-12-10 松谷化学工業株式会社 砂糖様味質をもつ新規甘味料、その製造法および用途
JP6013712B2 (ja) 2011-09-06 2016-10-25 合同会社希少糖食品 Ｄ−プシコースを有効成分とする生体代謝パラメーター改善剤
US20160151305A1 (en) * 2013-04-26 2016-06-02 Matsutani Chemical Industry Co., Ltd. Agent or method for treatement and/or prevention of accelerated energy expenditure and/or diminished energy expenditure functionality
JP6253451B2 (ja) * 2014-02-05 2017-12-27 学校法人自治医科大学 満腹感持続剤および満足感を維持する方法
JP6948670B2 (ja) * 2017-06-29 2021-10-13 松谷化学工業株式会社 Ｄ−プシコース及び大豆たんぱく質を有効成分とする生体機能改善用組成物
WO2020171144A1 (fr) * 2019-02-19 2020-08-27 国立大学法人香川大学 Composition orale utilisant une cléthra barbinervis contenant un composant biofonctionnel sous forme de corps végétal

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005213227A (ja) * 2004-01-30 2005-08-11 Teikoku Seiyaku Co Ltd Ｄ−プシコースの血糖上昇抑制効果の利用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005213227A (ja) * 2004-01-30 2005-08-11 Teikoku Seiyaku Co Ltd Ｄ−プシコースの血糖上昇抑制効果の利用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] MATSUO T. ET AL.: "Effects of dietary D-psicose on diurnal variation in plasma glucose and insulin concentrations of rats", accession no. STN Database accession no. (PREV200600345273) *
FASEB JOURNAL, vol. 20, no. 4, PART 1, May 2006 (2006-05-01), pages A594, XP003003028 *
MATSUO T. ET AL.: "D-psicose is a rare sugar that provides no energy to growing rats", JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, vol. 48, no. 1, February 2002 (2002-02-01), pages 77 - 80, XP002973184 *
MATSUO T. ET AL.: "Effects of oral acute administration and subchronic feeding of several levels of D-psicose in rats", JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, vol. 48, no. 6, 2002, pages 512 - 516, XP003003026 *
MATSUO T. ET AL.: "Less Body Fat Accumulation with D-Psicose Diet versus D-Fructose Diet", JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, vol. 30, 2001, pages 55 - 65, XP003003027 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008059625A1 (fr) * 2006-11-17 2008-05-22 National University Corporation Kagawa University Utilisation de la fonction de sucre rare en tant que promoteur de la migration de glucokinase depuis le noyau jusqu'au cytoplasme
US9259022B2 (en) 2013-03-15 2016-02-16 Tate & Lyle Ingredients Americas Llc Sweetener
US9491960B2 (en) 2013-03-15 2016-11-15 Tate & Lyle Ingredients Americas Llc Sweetener
US9635879B2 (en) 2013-03-15 2017-05-02 Tate & Lyle Ingredients Americas Llc Sweetener
US9854827B2 (en) 2013-03-15 2018-01-02 Tate & Lyle Ingredients Americas Llc Sweetener

Also Published As

Publication number Publication date
JP2007051137A (ja) 2007-03-01
JP5645183B2 (ja) 2014-12-24

Similar Documents

Publication Publication Date Title
JP5645183B2 (ja) Ｄ−プシコースを有効成分として含む肥満状態改善剤
EP3115052B1 (fr) D-psicose pour le traitement de l'artériosclérose
JP5421512B2 (ja) Ｄ−プシコースの血糖上昇抑制効果の利用
RU2358741C2 (ru) Композиции, обладающие функцией снижения жировой ткани тела, и продукты питания и напитки, содержащие такие композиции
JP6581902B2 (ja) エネルギー消費の促進および／またはエネルギー消費機能低下の治療および／または予防剤、または方法
KR101974442B1 (ko) 사이클로덱스트린을 포함하는 카테킨 생체 이용률 증진제
JP5240810B2 (ja) Ｄ−プシコースの血中ｄ−フラクトース濃度上昇抑制への使用
JPH09176019A (ja) 糖質分解消化酵素阻害剤並びにこれを配合した医薬品および飲食品
JP5847721B2 (ja) 高水溶性２−ヒドロキシプロピル−ベータシクロデキストリンを有効成分として含有する、肥満疾患の予防および治療用組成物
KR20160101724A (ko) 고지혈증 개선제 및 빈혈 개선 조성물, 요산치 저하 조성물 및 음식품
JP5116072B2 (ja) Ｄ−アロースの血糖上昇抑制効果の利用
JP2002012547A (ja) 糖質分解阻害剤、インスリン分泌抑制剤及び健康飲食物
EP1964568B1 (fr) Utilisation de l'effet anti-hypertensif/hypercardie du d-allose
KR20170044701A (ko) 지소화성 지속형 에너지 보급제
EP1283048B1 (fr) Agent thérapeutique pour l'amélioration de la fonction vésicale ou le traitement de perturbations urinaires et produit alimentaire ou boisson le contenant
JP2005213185A (ja) エネルギー補給および抗疲労飲食品
JP3634721B2 (ja) 高脂血症の予防又は治療剤
JP5394644B2 (ja) アスペルロシドまたはその類縁体を含む筋肉増強剤
JPH0995448A (ja) 血中ビオチン濃度の増加方法およびビオチン含有飲食品
KR20200130030A (ko) 당뇨병 환자와 잠재환자의 혈당조절효과가 있는 요구르트 조성물 제조방법
JP2011241216A (ja) モズク由来のフコイダンを含む食品
JP2003095941A (ja) 糖質消化酵素阻害剤、血糖値上昇抑制剤、肥満治療予防剤、糖尿病治療予防剤、健康飲食物
EP3834629A1 (fr) Composition et procédé de suppression d'augmentation du taux de glycémie
JP2004292355A (ja) 抗ストレス剤
JP6711539B2 (ja) 難消化性グルカンを含有する血糖上昇抑制剤およびその用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06781326

Country of ref document: EP

Kind code of ref document: A1